WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Central African Republic FM to visit ChinaEdwards and Towns lead Timberwolves into the 2nd round of the NBA playoffs for 1st time since 2004Chinese premier meets Indonesian presidentStrictly Come Dancing's Ellie Leach 'takes swipe at exMegan Fox showcases her curves in all black as she and Machine Gun Kelly bring their gothRyan Giggs' pregnant girlfriend Zara Charles cuts a casual figure in tightRobert Irwin reveals his 'red flags' after splitting from girlfriend Rorie BuckeyPlane crashes into river in AlaskaDance drama honors development of China's busiest portExperts challenge 'capacity' claims
2.7541s , 6503.1953125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gallery news portal